The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity
Open accessAbstract
The nephrotoxicity and ototoxicity associated with once-daily versus twice-daily administration of aminoglycosides was assessed in patients with suspected or proven gram-negative bacterial infections in a randomized, double-blind clinical trial. Patients who received therapy for ≥72 h were evaluated for toxicity. Patients also received concomitant antibiotics as deemed necessary for treatment of their infection. Plasma aminoglycoside concentrations, prospective aminoglycoside dosage adjustment, and serial audiologic and renal status evaluations were performed. The probability of occurrence of a nephrotoxic event and its relationship to doses and daily aminoglycoside exposure served as the main outcome measurement. One hundred twenty-three patients were enrolled in the study, with 83 patients receiving therapy for at least 72 h. For 74 patients plasma aminoglycoside concentrations were available for analysis, and the patients formed the group evaluable for toxicity. The primary infectious diagnosis for the patients who were enrolled in the study were bacteremia or sepsis, respiratory infections, skin and soft tissue infections, or urosepsis or pyelonephritis. Of the 74 patients evaluable for toxicity, 39 received doses twice daily and 35 received doses once daily and a placebo 12 h later. Nephrotoxicity occurred in 6 of 39 (15.4%) patients who received aminoglycosides twice daily and 0 of 35 patients who received aminoglycosides once daily. The schedule of aminoglycoside administration, concomitant use of vancomycin, and daily area under the plasma concentration-time curve (AUC) for the aminoglycosides were found to be significant predictors of nephrotoxicity by multivariate logistic regression analysis ( P ≤ 0.001). The time to a nephrotoxic event was significantly influenced by vancomycin use and the schedule of administration, as assessed by Cox proportional hazards modeling ( P ≤ 0.002). The results of the multivariate logistic regression analysis and the Cox proportional hazards modeling demonstrate that both the probability of occurrence and the time to occurrence of aminoglycoside nephrotoxicity are influenced by the schedule on which the aminoglycoside is administered as well as by the concomitant use of vancomycin. Furthermore, this risk of occurrence is modulated by the daily AUC for aminoglycoside exposure. These data suggest that once-daily administration of aminoglycosides has a predictably lower probability of causing nephrotoxicity than twice-daily administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
Nicolau, D. P., Freeman, C. D., Belliveau, P. P., Nightingale, C. H., Ross, J. W., & Quintiliani, R. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.650 · Cited by 641
Single or multiple daily doses of aminoglycosides: a meta-analysis
Barza, M., Ioannidis, J. P., Cappelleri, J. C., & Lau, J. (1996) · BMJ · doi:10.1136/bmj.312.7027.338 · Cited by 450
Moore, R. D., Smith, C. R., & Lietman, P. S. (1984) · Journal of Infectious Diseases · doi:10.1093/infdis/149.3.443 · Cited by 390
Nephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388
Self-citationOnce versus thrice daily gentamicin in patients with serious infections
Prins, J. M., Buller, H. R., Speelman, P., Kuijper, E. J., & Tange, R. A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90137-6 · Cited by 350
Once-daily aminoglycoside therapy
Gilbert, D. N. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.3.399 · Cited by 324
Powell, S. H., Thompson, W. L., Luthe, M. A., Stern, R. C., Grossniklaus, D. A., Bloxham, D. D., Groden, D. L., Jacobs, M. R., DiScenna, A. O., Cash, H. A., et al. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.918 · Cited by 272
The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-7_part_1-199310010-00006 · Cited by 258
Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value
Cantu, T. G., Yamanaka-Yuen, N. A., & Lietman, P. S. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.533 · Cited by 230
A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of Aminoglycosides
Bailey, T. C., Little, J. R., Littenberg, B., Reichley, R. M., & Dunagan, W. C. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.786 · Cited by 222
Munckhof, W. J., Grayson, M. L., & Turnidge, J. D. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/37.4.645 · Cited by 222
Ali, M. Z., & Goetz, M. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.796 · Cited by 220
Once-daily dosing decreases renal accumulation of gentamicin and netilmicin
Verpooten, G. A., Giuliano, R. A., Verbist, L., Eestermans, G., & De Broe, M. E. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.4 · Cited by 201
Kapusnik, J. E., Hackbarth, C. J., Chambers, H. F., Carpenter, T., & Sande, M. A. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/158.1.7 · Cited by 183
ter Braak, E. W. M. T., de Vries, P. J., Bouter, K. P., van der Vegt, S. G. L., Gc, D., Nortier, J. W. R., van Dijk, A. P. J., Verkooyen, R. P. A. J., & Verbrugh, H. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90099-y · Cited by 148
Marik, P. E., Lipman, J., Kobilski, S., & Scribante, J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.5.753 · Cited by 124
Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?
Nordström, L., Ringbert, H., Cronberg, S., Tjernström, Ö., & Walder, M. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.1.159 · Cited by 107
Netilmicin in the Treatment of Gram-Negative Bacteremia: Single Daily versus Multiple Daily Dosage
Sturm, A. W. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.5.931 · Cited by 101
Guide for the Evaluation of Hearing Handicap
(1979) · JAMA · doi:10.1001/jama.1979.03290450053025 · Cited by 95
Wood, C. A., Norton, D. R., Kohlhepp, S. J., Kohnen, P. W., Porter, G. A., Jr., Houghton, D. C., Brummett, R. E., Wm, B., & Gilbert, D. N. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.1.13 · Cited by 88
Tulkens, P. M. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.suppl_c.49 · Cited by 87
Hollender, L. F., Bahnini, J. M., de Manzini, N., Lau, W. Y., Fan, S. T., Hermansyur, K., Benny, P., Husni, A. N., Sutjipto, & Lorber, R. R. (1989) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/23.5.773 · Cited by 78
Parsons, A. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511752377.001 · Cited by 74
Guide for the Evaluation of Hearing Handicap
Catlin, F. I. (1979) · Otolaryngologic Clinics of North America · doi:10.1016/s0030-6665(20)32453-1 · Cited by 70
Rozdzinski, E., Kern, W. V., Reichle, A., Moritze, T., Schmeiser, T., Gaus, W., & Kurrle, E. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.4.585 · Cited by 69
Giamarellou, H., Yiallouros, K., Petrikkos, G. L., Moschovakis, E., Vavouraki, E. A., Voutsinas, D., & Sfikakis, P. P. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.suppl_c.73 · Cited by 64
Gilbert, D. N. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.816 · Cited by 57
Single Daily Dosing of Aminoglycosides
Preston, S. L., & Briceland, L. L. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04368.x · Cited by 51
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationDiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationKrause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027029 · Cited by 1,149
Pharmacokinetics and Pharmacodynamics of Antibacterial Agents
Levison, M. E., & Levison, J. H. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.008 · Cited by 557
Metadata
- Authors
- Rybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., & Drusano, G. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1999-07
- Volume
- 43
- Issue
- 7
- Pages
- 1549-1555
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2097945561
- Cited by
- 431
- References
- 32
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.